Beigene Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BEIGENE, and what generic alternatives to BEIGENE drugs are available?
BEIGENE has one approved drug.
There are eleven US patents protecting BEIGENE drugs.
There are sixty-four patent family members on BEIGENE drugs in twenty-nine countries and eleven supplementary protection certificates in eleven countries.
Drugs and US Patents for Beigene
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | 11,851,437 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | 11,884,674 | ⤷ Sign Up | ⤷ Sign Up | ||||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | 11,786,531 | ⤷ Sign Up | ⤷ Sign Up | ||||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Beigene | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Beigene Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 2022071072 | ⤷ Sign Up |
Denmark | 2989106 | ⤷ Sign Up |
South Africa | 201900919 | ⤷ Sign Up |
Eurasian Patent Organization | 028756 | ⤷ Sign Up |
Portugal | 2989106 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Beigene Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2989106 | 2290500-4 | Sweden | ⤷ Sign Up | PRODUCT NAME: ZANUBRUTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/21/1576 20211123 |
2989106 | 4/2022 | Austria | ⤷ Sign Up | PRODUCT NAME: ZANUBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1576 (MITTEILUNG) 20211123 |
2989106 | C202230011 | Spain | ⤷ Sign Up | PRODUCT NAME: ZANUBRUTINIB O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO.; NATIONAL AUTHORISATION NUMBER: EU/1/21/1576; DATE OF AUTHORISATION: 20211122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1576; DATE OF FIRST AUTHORISATION IN EEA: 20211122 |
2989106 | CA 2022 00008 | Denmark | ⤷ Sign Up | PRODUCT NAME: ZANUBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1576 20211123 |
2989106 | C02989106/01 | Switzerland | ⤷ Sign Up | FORMER OWNER: BEIGENE, LTD., KY |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.